ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS

Data shows a rise in specific treatment demand; a shift in patient consultation and the rising role of facial volume restoration

• 67% of patients say MWL treatment changed their goals toward improving appearance, not just weight reductionⁱ.
• Nearly half of MWL patients (47%) were reported by HCPs to benefit most from hyaluronic acid injectable fillers when addressing post-weight-loss facial concernsⁱⁱ.
• 60% of consumers receiving GLP-1 medications obtain them from providers who also offer aesthetic treatments, up from 49% in late 2024ⁱⁱⁱ.

IRVINE, Calif., March 4, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, shares new data illustrating how the rapid adoption of Medical Weight Loss (MWL) treatments is changing patient behavior, aesthetic priorities, and treatment demand, particularly as facial volume loss emerges as a leading concern.

View PDF

"Allergan Aesthetics is committed to equipping our customers with data-driven insights, education, and consultation tools to help guide patients safely and effectively through these changes," said Glen Curran, Senior Vice President at Allergan Aesthetics. "We're seeing this new patient population enter aesthetics with different concerns, different goals, and a strong desire for individualized, long-term treatment and care, particularly when it comes to restoring facial balance and volume."

Data Highlights: How GLP-1–Associated Weight Loss Is Changing Aesthetic Care

The data underscores a broader evolution in the aesthetics landscape; patients undergoing medical weight loss are entering aesthetic practices with distinct needs tied to facial volume, structure, and skin quality, many for the first time. As rapid weight loss can accelerate visible changes in the face, early consultation and proactive treatment planning are critical to helping patients understand their options and achieve balanced, natural looking outcomes. For many of these patients, hyaluronic acid fillers can play an important role in addressing volume loss and supporting natural-looking outcomes that align with their overall transformation journey.

Consumer interest in aesthetics is rising with 40% of MWL patients considering a professionally administered aesthetic treatment in a physician's office or medspa^iv. Notably, aesthetic practices are increasingly serving as an entry point into the category; 60% of consumers using GLP-1 medications now receive them from healthcare providers who also offer aesthetic treatments, up from roughly half just one year ago^v.

According to Allergan Aesthetics studies and consumer market research, physicians report that MWL is driving meaningful shifts in facial concerns, treatment preferences, and patient demand:

• Facial volume loss is the leading aesthetic impact, with 61% of GLP-1 patients experiencing midface volume loss, followed by skin laxity (50%), and facial wrinkles/folds (35%)^vi.
• Hyaluronic acid (HA) dermal fillers are a primary treatment option, with 81% of HCPs identifying HA fillers as a top nonsurgical modality following GLP-1 related weight loss^vii.
• One-third of physicians (33%) say GLP-1 usage has increased the overall volume of dermal filler injections in their practice^viii.

Allergan Aesthetics has been studying the intersection of MWL and aesthetic medicine since early 2022. Allergan Aesthetic consumer market research closely mirrors data the company presented at the 2025 American Society for Dermatologic Surgery (ASDS) Annual Meeting and was published in January 2026 in the Aesthetic Surgery Journal's Open Forum, "Nonsurgical Aesthetic Treatment of the Face and Neck in GLP-1 Receptor Agonist Weight Loss Patients: Experience-Based Considerations," demonstrating that patients are increasingly seeking physician-guided aesthetic solutions to address changes in facial appearance following weight loss.

"As a dermatologist, I've seen firsthand how medical weight loss can significantly impact the face," said Dr. Joely Kaufman, a board-certified dermatologist in Miami, FL. "This data reflects what we're seeing in practice – patients who are excited about their weight loss success are looking for personalized, medically appropriate solutions that restore balance and confidence."

Through proprietary consumer research, physician collaboration, and data shared at leading medical forums, the company continues to translate emerging trends into actionable insights for healthcare providers.

Download our MWL & Aesthetics infographic to learn more.

Media Contact

Kate McShane
Director, Corporate Communications
Cell +1862.325.6984
Email [email protected]

About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2022 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

*An AbbVie company

SOURCE AbbVie